Last reviewed · How we verify
3HP-2827
At a glance
| Generic name | 3HP-2827 |
|---|---|
| Sponsor | 3H (Suzhou) Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations (PHASE1, PHASE2)
- A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 3HP-2827 CI brief — competitive landscape report
- 3HP-2827 updates RSS · CI watch RSS
- 3H (Suzhou) Pharmaceuticals Co., Ltd. portfolio CI